Company insider dossier

BioLife Solutions Inc insider intelligence

BLFS filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Medical Instruments & Supplies Data API
12/100

Concentrated distribution

99/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Instruments & Supplies
Latest evidence
8 Sep 2026

Investment committee read

Concentrated distribution

Priced common-share disposals are concentrated enough to warrant review, but they are not treated as a standalone bearish forecast.

Review exposure and filing context

Evidence in favour

  • Participation spans 6 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 08 Sep 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction12Concentrated distribution
Confidence99Deep evidence
Named insiders6participating in the tape
Controlled events18directional common-share events
Acquisition value$0normalized amount
Disposal value$28.4Mnormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

37.1032.4127.7323.0518.36 Disposal · 8 Sep 2026 · $36.3KDisposal · 8 Sep 2026 · $22.2KDisposal · 8 Sep 2026 · $12.6KDisposal · 17 Jul 2026 · $8.0KDisposal · 7 Jul 2026 · $23.5KDisposal · 7 Jul 2026 · $14.3KDisposal · 7 Jul 2026 · $8.1KDisposal · 18 Jun 2026 · $72.3KDisposal · 18 Jun 2026 · $24.4KDisposal · 18 Jun 2026 · $14.7KDisposal · 18 Jun 2026 · $12.2KDisposal · 18 Jun 2026 · $10.9KDisposal · 8 Jun 2026 · $26.8KDisposal · 8 Jun 2026 · $16.4KDisposal · 8 Jun 2026 · $9.3KDisposal · 21 May 2026 · $15.4MDisposal · 20 May 2026 · $5.9MDisposal · 19 May 2026 · $6.8M
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
34.95 USD
One-week move
-0.9%
Four-week move
-0.3%
Fair-value gap
+53.8%
Trend signal
Active
Relative strength
23.2

Directional balance

Controlled event mix

0.0%acquisition
Acquisition events
0
Disposal events
18
Net value
-$28.4M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

029 Jun
306 Jul
113 Jul
020 Jul
027 Jul
003 Aug
010 Aug
017 Aug
024 Aug
031 Aug
307 Sep
014 Sep

Named participants

Insider conviction by person

DE, GREEF RODERICKDirector, President and CEO281 events
WERNER, SEANChief Technology Officer252 events
CASDIN, PARTNERS MASTER FUND, L.P.10% Owner223 events
BERARD, TODDChief Marketing Officer204 events
MATHEW, ABY J.EVP & Chief Scientific Officer204 events
WICHTERMAN, TROYChief Financial Officer204 events

Evidence quality

Security and transaction context

Common equity18
Equity compensation0
Options and derivatives0
Other securities0

Role architecture

Who is participating

Other executive10
Finance leadership4
Large holder3
CEO and chair1

Transaction evidence

Auditable BLFS filing ledger

Showing 1 to 18 of 18.

WICHTERMAN, TROYChief Financial Officer
DisposalCommon equity
1026 sharesCommon Stock
$36.3KDirectional evidence
MATHEW, ABY J.EVP & Chief Scientific Officer
DisposalCommon equity
627 sharesCommon Stock
$22.2KDirectional evidence
BERARD, TODDChief Marketing Officer
DisposalCommon equity
356 sharesCommon Stock
$12.6KDirectional evidence
WERNER, SEANChief Technology Officer
DisposalCommon equity
275 sharesCommon Stock
$8.0KDirectional evidence
WICHTERMAN, TROYChief Financial Officer
DisposalCommon equity
844 sharesCommon Stock
$23.5KDirectional evidence
MATHEW, ABY J.EVP & Chief Scientific Officer
DisposalCommon equity
516 sharesCommon Stock
$14.3KDirectional evidence
BERARD, TODDChief Marketing Officer
DisposalCommon equity
293 sharesCommon Stock
$8.1KDirectional evidence
DE, GREEF RODERICKDirector, President and CEO
DisposalCommon equity
2775 sharesCommon Stock
$72.3KDirectional evidence
WICHTERMAN, TROYChief Financial Officer
DisposalCommon equity
937 sharesCommon Stock
$24.4KDirectional evidence
MATHEW, ABY J.EVP & Chief Scientific Officer
DisposalCommon equity
564 sharesCommon Stock
$14.7KDirectional evidence
BERARD, TODDChief Marketing Officer
DisposalCommon equity
470 sharesCommon Stock
$12.2KDirectional evidence
WERNER, SEANChief Technology Officer
DisposalCommon equity
420 sharesCommon Stock
$10.9KDirectional evidence
WICHTERMAN, TROYChief Financial Officer
DisposalCommon equity
1026 sharesCommon Stock
$26.8KDirectional evidence
MATHEW, ABY J.EVP & Chief Scientific Officer
DisposalCommon equity
627 sharesCommon Stock
$16.4KDirectional evidence
BERARD, TODDChief Marketing Officer
DisposalCommon equity
356 sharesCommon Stock
$9.3KDirectional evidence
CASDIN, PARTNERS MASTER FUND, L.P.10% Owner
DisposalCommon equity
650000 sharesCommon Stock, par value $0.001 per share
$15.4MDirectional evidence
CASDIN, PARTNERS MASTER FUND, L.P.10% Owner
DisposalCommon equity
250000 sharesCommon Stock, par value $0.001 per share
$5.9MDirectional evidence
CASDIN, PARTNERS MASTER FUND, L.P.10% Owner
DisposalCommon equity
300000 sharesCommon Stock, par value $0.001 per share
$6.8MDirectional evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context